![]() ![]() “China has embarked on the largest investment in research and development in the history of our planet and has identified areas such as renewable energy, the digital economy, biotechnology and bimolecular sciences as major sectors for growth – UNSW's position as a research intensive university with strengths in these areas means we are an obvious partner for China's growth.” “UNSW is one of Australia's top ranked universities for ARC linkage grants and has a track record of strong industry linkages – my role is to use this proven model as a blueprint for increasing the University’s engagement in China,” said Pearcey. The position, based within UNSW International, aims to promote research collaborations with Chinese institutions and industry partners. There were fewer major protocol violations at FR in cases subjected to PR than in cases not submitted for PR, indicating a major impact on eliminating protocol non-compliance as a variable influencing outcomes in cooperative group trials.Former Chief Executive Officer of the Australia China Business Council, Laurie Pearcey, has been appointed the inaugural Director of China Strategy and Development at the University of New South Wales. Interventions were frequently required and offered an excellent opportunity for investigator education. We believe this to be the first centralized pre-therapy review and intervention in a U.S. There was widespread acceptance of the concept of centralized pre-radiation quality assurance review and willingness both to submit diagnostic, response, and radiation treatment planning images and to implement recommended changes. Five (39%) of the 13 disparate reviews occurred in the initial 13 of 176 (11%) reviews, suggesting a learning curve in interpreting protocol intent.Ĭonclusions. The causes for disparity were interpretation of “equivocal” disease (4), gross disease (5), and adequacy of margin (3), or difference in studies available for the two reviews (1). There were discrepancies between the PR and FR in 13 of the 176 cases. In only 19 were modifications not made, suggesting widespread willingness to change radiation field design to achieve protocol compliance. At PR, modifications to achieve protocol compliance were suggested in all but 40 cases. Sixteen of 40 (40%) of cases not submitted for PR were judged major protocol violations at FR, compared with 23 of 176 cases (13%) subjected to PR. Thirty-nine of 53 (74%) cases from institutions exempt from the requirement for pre-radiation data submission and 137 of 163 (84%) cases from non-exempt institutions submitted data for PR, indicating widespread and voluntary compliance with centralized PR at Quality Assurance Review Center (QARC). Forty-seven cases were invaluable (incomplete submission of data) and 31 patients were removed from study before XRT leaving a total of 216 patients with both PR and FR for analysis. ![]() After the first 28 cases, the directorship of QARC changed. POG 9426 enrolled 294 patients, including 246 from 85 POG institutions and 48 from 33 CCG institutions. The 9426 Protocol Coordinators conducted a Final Review (FR) of protocol compliance at a later date. In some cases, multiple revisions were required. Treating radiation oncologists were notified within 24 hours as to whether plans were compliant or required revision. Before XRT, initial and response imaging and XRT planning films were submitted for Pre-radiation Review (PR) at QARC. A minimum 2 cm XRT field margin was required on all imaged diseases, as a first step in the transition from historical standard XRT field design to image-based field design. Partial responders to 2 cycles of ABVE received 2 more cycles of ABVE before XRT. Early complete responders to 2 cycles of ABVE received 25 Gy of radiation therapy (XRT) to involved field(s). POG 9426 investigated response-based therapy in Stages IA, IIA, and IIIA 1 HD without large mediastinal masses. This report documents the impact of this quality assurance program. To reduce protocol non-compliance as a confounding variable impacting trial outcome, Pediatric Oncology Group (POG) mandated pre-radiation quality assurance review in POG 9426, a trial in pediatric early stage Hodgkin's disease (HD). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |